Navigation Links
Serina Therapeutics Awarded Patent for Its Core Polymer Drug Delivery Technology
Date:5/20/2011

HUNTSVILLE, Ala., May 20, 2011 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company, announced that the company was awarded a patent from the United States Patent and Trademark Office covering its polymer technology.  The patent entitled "Polyoxazoline and compositions comprising the same" (U.S. Patent No. 7,943,141) covers the synthesis and composition of polyoxazolines for the delivery of different drug molecules.      

The patent represents years of groundbreaking research in the development of safe polyoxazoline polymers for drug delivery.  It is the first of many patents that Serina has applied for.  "This patent award validates our invention and design of a novel drug delivery platform and allows Serina the opportunity to advance some of its proprietary ideas towards full development and eventually commercialization," said Dr. Michael D. Bentley, Chief Scientific Officer and cofounder of the company. "We are now in a position to build a strong pipeline of polymer therapeutic molecules."  

About Serina

Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms.  The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled nine approved polyethylene glycol (PEG) products for various pharmaceutical partners.  Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.  

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com

Media Contact:  Karen Petersen, 256-327-9434


'/>"/>
SOURCE Serina Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
2. Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics
3. Regency Therapeutics and Daiichi Sankyo Announce Launch and Commercial Availability of SPRIX® (ketorolac tromethamine) Nasal Spray
4. Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
5. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
6. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
7. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
8. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
9. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
10. Echo Therapeutics Expands Into New Headquarters in Philadelphia
11. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... excited to announce the launch of its Mediceutical line of products, a line of ... of clinical conditions. Founded in 2013, Forté spent more than two years researching and ... http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information ... (Electronic Medical Records) market in a recent white paper.  ... switches, Increased physician usage, a growing market are among ... noted in Kalorama,s report EMR 2016: The ... marks Kalorama,s seventh complete study of the EMR industry, ...
(Date:5/2/2016)... 2, 2016  While nearly three-quarters of Americans (71%) ... on their health, only about half report taking any ... results of a new survey announced today by Hologic ... of National Osteoporosis Month, Hologic is raising awareness of ... 56 million Americans. Osteoporosis is a disease ...
Breaking Medicine Technology:
(Date:5/3/2016)... California (PRWEB) , ... May 03, 2016 , ... Cosmetic ... practice in late 2014, incorporating the injectable filler into his menu of services ... aesthetic transformation. Now, more than a year later, he’s still improving his approach to ...
(Date:5/3/2016)... FORT WORTH, Texas (PRWEB) , ... May 03, 2016 , ... ... some of the signs of pet anxiety. "Pet owners often think anxiety only ... be sending stress signals in other ways, and there’s things that be done about ...
(Date:5/3/2016)... Texas (PRWEB) , ... May 03, 2016 , ... ... today announced that it is launching a new client service center in La ... Houston, Texas, and will provide the full range of Empyrean client services. , ...
(Date:5/3/2016)... ... , ... Each year, about 800,000 people suffer from cerebral vascular accidents, or ... account for one death every four minutes. Many people who survive a stroke ... launching a video series called “Your Brain,” in conjunction with its medical journal “Balance,” ...
(Date:5/3/2016)... Indianapolis, IN (PRWEB) , ... May 03, 2016 ... ... employee benefits advisory organization, announces Benefits Alliance Insurance Services as the latest addition ... powerhouse Southern California-based Firm comprised of Partners Wayne Blasman, David Styles, and Paul ...
Breaking Medicine News(10 mins):